碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BDX 碧迪医疗

盘前交易 07-23 05:16:20 EDT

231.09

+0.35

+0.15%

最高232.22	最低229.04	成交量86.67万
今开231.27	昨收230.74	日振幅1.38%
总市值667.87亿	流通市值666.33亿	总股本2.89亿
成交额2.00亿	换手率0.30%	流通股本2.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BDX","market":"US","secType":"STK","nameCN":"碧迪医疗","latestPrice":231.09,"timestamp":1721678400000,"preClose":230.74,"halted":0,"volume":866743,"delay":0,"floatShares":288343653,"shares":289006461,"eps":4.526108,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.35,"latestTime":"07-23 05:16:20 EDT","open":231.27,"high":232.22,"low":229.04,"amount":200214590.73207,"amplitude":0.013782,"askPrice":233,"askSize":7,"bidPrice":228.41,"bidSize":100,"shortable":3,"etf":0,"ttmEps":4.526108,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721741400000},"adr":0,"listingDate":-240782400000,"adjPreClose":231.09,"adrRate":0,"dividendRate":0.016098,"postHourTrading":{"tag":"盘后","latestPrice":231.09,"preClose":231.09,"latestTime":"19:35 EDT","volume":69985,"amount":16172952.09,"timestamp":1721691309777},"volumeRatio":0.7503924062294076,"impliedVol":0.2654,"impliedVolPercentile":0.9124},"requestUrl":"/m/hq/s/BDX/wiki","defaultTab":"wiki","newsList":[{"id":"2450848267","title":"美国食品和药物管理局示意百通狄金森公司血液试管短缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2450848267","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450848267?lang=zh_cn&edition=full","pubTime":"2024-07-11 00:49","pubTimestamp":1720630166,"startTime":"0","endTime":"0","summary":"    路透7月10日 - 美国食品和药物管理局周三向实验室和医疗服务提供商发出警告，称用于诊断细菌和真菌感染的Becton Dickinson  血液试管出现短缺。背景上个月，Becton 公司向  发函警告，由于供应商塑料瓶供应量减少，未来几个月 BACTEC 血液培养基供应可能会出现延误。Becton 公司表示正在采取措施解决这一问题，包括使用空运和修改生产计划以实现快速生产。数字美国疾病控制与预防中心称，美国每年至少有 170 万成年人患败血症，近 27 万人因此死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0289961442.SGD","LU0289739343.SGD","LU1571399168.USD","LU1854103824.USD","BK4082","BK4585","LU0511384066.AUD","IE00BFXG1179.USD","LU1854104046.USD","BK4504","LU0266013472.USD","BDX"],"gpt_icon":0},{"id":"2441051879","title":"碧迪医疗举债232亿元加码重症监护，能否扭转业绩下滑颓势？","url":"https://stock-news.laohu8.com/highlight/detail?id=2441051879","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441051879?lang=zh_cn&edition=full","pubTime":"2024-06-07 18:52","pubTimestamp":1717757573,"startTime":"0","endTime":"0","summary":"为了筹集收购资金，碧迪医疗计划动用约10亿美元的现金，以及32亿美元的新债务，这一债务折合人民币约232亿元。碧迪医疗举债收购的首要原因或许为业绩压力，其净利润在近两年半内连续下滑。期间碧迪医疗实现净利润14.84亿美元，同比下降16.6%；2022年实现净利润17.79亿美元，同比下降14.96%。本次集采中，碧迪医疗的留置针中标价格包括4.8元、4.2元、13.99元等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071856149f241618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071856149f241618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0266013472.USD","BK4588","BK4585","LU0511384066.AUD","BK4504","LU0289961442.SGD","LU1571399168.USD","LU0289739343.SGD","BDX","BK4082","LU1854103824.USD","LU1854104046.USD"],"gpt_icon":0},{"id":"2441264367","title":"爱德华生命科学作价42亿美元向碧迪医疗出售重症监护业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2441264367","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441264367?lang=zh_cn&edition=full","pubTime":"2024-06-05 06:57","pubTimestamp":1717541832,"startTime":"0","endTime":"0","summary":"爱德华生命科学（Edwards Lifesciences）近日宣布与碧迪医疗（Becton, Dickinson and Company）达成最终协议，将旗下重症监护全线产品以42亿美元现金方式出售给碧迪医疗。基于此项协议，爱德华不再继续推进此前宣布的重症监护业务分拆计划。该交易预计将在2024年底前完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605065712af8bf51f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605065712af8bf51f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1571399168.USD","LU1854104046.USD","LU0289961442.SGD","BK4504","LU1854103824.USD","BK4082","LU0289739343.SGD","BDX","BK4588","LU0511384066.AUD","BK4585","LU0266013472.USD"],"gpt_icon":0},{"id":"2440741306","title":"碧迪医疗(BDX)涨逾2.6% 将以42亿美元现金收购爱德华生命科学(EW)重症监护产品组","url":"https://stock-news.laohu8.com/highlight/detail?id=2440741306","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440741306?lang=zh_cn&edition=full","pubTime":"2024-06-04 01:28","pubTimestamp":1717435701,"startTime":"0","endTime":"0","summary":"金吾财讯 | 碧迪医疗(BDX)股价震荡走高，高见241.635美元，涨近4%，截至发稿，仍涨2.67%，报238.17美元，成交额2.41亿美元。日前，碧迪医疗(BDX)和爱德华生命科学(EW)宣布了一项最终协议，根据该协议，碧迪医疗将以42亿美元现金收购Edwards重症监护产品组，后者是先进监测解决方案的全球领导者，从而释放新的价值创造机会并增强比对医疗的智能互联护理解决方案组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604012836958a8ced&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604012836958a8ced&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","LU1571399168.USD","LU0511384066.AUD","LU1854104046.USD","LU0266013472.USD","LU0289961442.SGD","LU1854103824.USD","BDX","LU0289739343.SGD","BK4588","EW","BK4504","BK4585","BK4567"],"gpt_icon":0},{"id":"2440528462","title":"碧迪医疗(BDX.US)42亿美元巨资收购爱德华生命科学(EW.US)重症监护部门 盘前涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440528462","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440528462?lang=zh_cn&edition=full","pubTime":"2024-06-03 20:00","pubTimestamp":1717416019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，碧迪医疗宣布，已同意以42亿美元现金收购爱德华生命科学的重症监护部门，此举旨在拓展其医疗监测产品线。此外，自2015年起担任爱德华生命科学重症监护部门副总裁的Katie Szyman，将负责领导碧迪医疗的重症监护业务。据了解，爱德华生命科学重症监护部门的产品线包括Swan Ganz肺动脉导管、微创传感器、组织血氧仪传感器以及监视器等。截至发稿，碧迪医疗盘前涨1.45%，报235.33美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BDX","LU1571399168.USD","EW","LU0511384066.AUD","LU0266013472.USD","LU0289739343.SGD","BK4082","LU1854103824.USD","BK4504","BK4588","LU1854104046.USD","BK4585","LU0289961442.SGD","BK4567"],"gpt_icon":0},{"id":"2440846654","title":"BUZZ-Edwards Lifesciences 上涨；将以 42 亿美元出售重症监护部门","url":"https://stock-news.laohu8.com/highlight/detail?id=2440846654","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440846654?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:57","pubTimestamp":1717412248,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    6月3日 - ** 医疗设备制造商爱德华生命科学公司  股价盘前上涨3.4%至89.80美元 ** 称已同意 (link) 将其重症监护产品部门出售给 Becton Dickinson   ，全现金交易价值 42 亿美元。** 根据这项协议，公司将不再继续推进此前宣布的分拆重症监护产品部门的计划 - EW ** 预计交易将于 2024 年底完成** BDX 表示，预计将以约 10 亿美元现金和 32 亿美元新债为交易提供资金** 截至上次收盘，EW年累计上涨13.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BUZZ","EW","BK4588","LU1571399168.USD","BK4585","BK4504","BDX","BK4567","LU1854104046.USD","LU0289961442.SGD","LU0511384066.AUD","LU0289739343.SGD","LU0266013472.USD","LU1854103824.USD"],"gpt_icon":0},{"id":"2440652814","title":"更新版 1-爱德华生命科学公司将以 42 亿美元的价格向 Becton Dickinson 公司出售关键产品部门","url":"https://stock-news.laohu8.com/highlight/detail?id=2440652814","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440652814?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:50","pubTimestamp":1717411852,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (添加详细信息)    路透6月3日 - 爱德华生命科学公司  周一表示，已同意将其重症监护产品部门出售给Becton Dickinson 公司  ，全现金交易价值42亿美元。 根据这项协议，总部位于加利福尼亚州的爱德华兹公司表示，它不再寻求分拆之前宣布的重症监护产品部门。  这家医疗设备制造商曾 在 4 月 (link) ，表示将在 2024 年底分拆重症监护部门，集中精力发展更大的心脏设备业务。     在满足或放弃某些成交条件的前提下，该交易预计将于2024年底完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0266013472.USD","LU0289961442.SGD","BK4504","LU1854103824.USD","EW","LU1854104046.USD","BK4082","LU0511384066.AUD","LU0289739343.SGD","BDX","LU1571399168.USD","BK4567","BK4585"],"gpt_icon":0},{"id":"2440146557","title":"爱德华生命科学公司将以 42 亿美元的价格向 Becton Dickinson 公司出售其关键产品部门","url":"https://stock-news.laohu8.com/highlight/detail?id=2440146557","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440146557?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:37","pubTimestamp":1717411056,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月3日 - 爱德华生命科学公司（Edwards Lifesciences   ）周一表示，该公司已同意将其重症监护产品部门出售给Becton, Dickinson and Co   公司，该交易为全现金交易，价值42亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","LU1854103824.USD","BDX","BK4082","LU1571399168.USD","LU0289961442.SGD","BK4504","EW","BK4588","LU0266013472.USD","LU0289739343.SGD","BK4585","BK4567","LU0511384066.AUD"],"gpt_icon":0},{"id":"2434866084","title":"碧迪医疗2024财年第一财季实现净利润5.37亿美元，同比增加16.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434866084","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434866084?lang=zh_cn&edition=full","pubTime":"2024-05-11 00:16","pubTimestamp":1715357814,"startTime":"0","endTime":"0","summary":"3月31日，碧迪医疗公布财报，公告显示公司2024财年第一财季净利润为5.37亿美元，同比增加16.74%；其中营业收入为50.45亿美元，同比增加4.65%，每股基本收益为1.85美元。从资产负债表来看，碧迪医疗总负债285.09亿美元，其中短期债务20.16亿美元，资产负债比为1.90，流动比率为1.42。机构评级：截至2024年3月31日，当前有12家机构对碧迪医疗目标价做出预测，其中目标均价为277.42美元，其中最低目标价为240.00美元，最高目标价为315.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051100170687516cc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051100170687516cc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BDX"],"gpt_icon":0},{"id":"2432010086","title":"BUZZ-百通公司上调 2024 年利润预期，业绩攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2432010086","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432010086?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:48","pubTimestamp":1714657726,"startTime":"0","endTime":"0","summary":"    5月2日 - ** 医疗设备制造商 Becton Dickinson    股价上涨 ~3.2% 至 241.09 美元 ** 该公司将  年度利润预期从之前的每股 12.82 美元至 13.06 美元上调至每股 12.95 美元至 13.15 美元。** 威廉-布莱尔公司分析师安德鲁-布拉克曼表示：\"从长远来看，我们对北斗公司的前景保持乐观，因为该公司似乎正在顺利实现其北斗 2025 承诺。** 公司报告第二季度每股净利润为 3.17 美元，高于分析师预计的每股 2.97 美元 - LSEG 数据** 包括本交易日走势在内，该股今年累计下跌 4.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU0511384066.AUD","LU1571399168.USD","BK4148","LU0289739343.SGD","LU1854103824.USD","LU0289961442.SGD","LU1854104046.USD","BDC","BK4082","BK4585","BK4504","BUZZ","BDX","BK4588"],"gpt_icon":0},{"id":"2432099196","title":"Becton Dickinson and Co 公布截至 3 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2432099196","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432099196?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:32","pubTimestamp":1714656733,"startTime":"0","endTime":"0","summary":"   * Becton Dickinson and Co   公布的截至3月底的季度调整后每股收益为3.17美元，高于去年同期的每股收益2.86美元。13 位分析师对该季度的平均预期为每股收益 2.97 美元。华尔街预期为每股收益 2.92 美元至 3.02 美元。* 据报告，Becton Dickinson and Co 公司本季度每股收益为 1.85 美元。* 公司季度净收入为 5.37 亿美元。* 本季度 Becton Dickinson and Co 的股价下跌了 5.5%，今年迄今为止下跌了 4.1%。* 华尔街对 Becton Dickinson and Co 的 12 个月目标股价中位数为 275.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0289961442.SGD","LU0266013472.USD","LU0511384066.AUD","LU1854104046.USD","BK4082","BK4585","BK4588","BK4504","BDXA","LU1571399168.USD","BDX","LU1854103824.USD"],"gpt_icon":0},{"id":"2432467967","title":"手术设备需求强劲，百通迪金森上调利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2432467967","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432467967?lang=zh_cn&edition=full","pubTime":"2024-05-02 19:25","pubTimestamp":1714649144,"startTime":"0","endTime":"0","summary":"    路透5月2日 - 拜登迪金森  周四上调了全年利润预期，第二季度利润超过预期，因为该集团依靠的是对其手术设备和注射器的强劲需求。提供手术和重症监护设备的介入部门本季度的销售额为 12.9 亿美元，高于预期的 11.9 亿美元。集团总收入同比增长 4.6%，达到 50.5 亿美元，略高于预期的 50.4 亿美元。截至3月31日的第二季度，Becton公司调整后每股利润为3.17美元，高于分析师预计的每股2.97美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU1732800096.USD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","LU2125909593.SGD","BK4581","BSX","LU1057294990.SGD","SG9999001176.SGD","BK4592","LU1267930813.SGD","SG9999001440.SGD","LU0316494557.USD","ABT","DHR","SGXZ57979304.SGD","LU0708995401.HKD","LU2106854487.HKD","LU1923621640.USD","LU2125909247.SGD","LU1923622291.USD","LU2125910336.SGD","LU1988902786.USD","LU0266013472.USD","LU1571399168.USD","SG9999001176.USD","LU2468319806.SGD","LU2125910179.SGD","IE00B19Z9505.USD","LU2347655156.SGD","LU1914381329.SGD","LU0238689110.USD","LU1244550577.SGD","BK4548","LU0792757196.USD","LU1291159041.SGD","IE0002270589.USD","LU0061474960.USD","LU1032955483.USD","LU1732799900.SGD","LU2092937221.SGD","SGXZ23171101.USD","IE00BZ1G4Q59.USD","LU2125909916.SGD","TMO","LU1261432733.SGD","BDX","LU0353189763.USD","JNJ","LU0122379950.USD"],"gpt_icon":0},{"id":"2427871310","title":"BUZZ-J&J 医疗技术部门销售额未达预期，医疗器械制造商业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2427871310","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2427871310?lang=zh_cn&edition=full","pubTime":"2024-04-16 23:25","pubTimestamp":1713281142,"startTime":"0","endTime":"0","summary":"    4月16日 - ** 强生  医疗设备部门公布第一季度 ，销售额为78.2亿美元，低于华尔街预期的78.8亿美元，LSEG数据显示，医疗设备制造商股价下跌1%至3%。** 史赛克  下跌1%，Zimmer Biomet  下跌1.2%，美敦力  下跌1.4%，安捷伦  下跌2.4%，拜登迪金森  下跌0.9%，博士伦   下跌1.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBH","IE0002270589.USD","BK4504","LU1732800096.USD","LU1261432733.SGD","LU1032955483.USD","LU0976567544.SGD","ISRG","LU2362540622.SGD","LU2362541273.HKD","LU1196500208.SGD","LU2133065610.SGD","LU2347655156.SGD","JNJ","LU1221951046.USD","SG9999002232.USD","LU1732799900.SGD","BK4082","BK4559","LU2362541513.USD","LU0122379950.USD","LU1430594728.SGD","LU2106854487.HKD","IE00B19Z3B42.SGD","LU0211331839.USD","LU1221951129.SGD","LU0006061336.USD","LU1804176565.USD","LU1023059063.AUD","SG9999002224.SGD","BK4121","BK4550","A","LU1059921491.USD","BUZZ","BDX","LU2041044095.USD","LU1057294990.SGD","MDT","BK4548","LU1791710400.SGD","LU1585245621.USD","LU0266013472.USD","BK4007","LU0158827948.USD","LU0792757196.USD","LU0511384066.AUD","SYK","LU2092937221.SGD","LU1791710582.SGD"],"gpt_icon":0},{"id":"2421185380","title":"Becton Dickinson 将增加国内注射器生产量","url":"https://stock-news.laohu8.com/highlight/detail?id=2421185380","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2421185380?lang=zh_cn&edition=full","pubTime":"2024-03-21 18:57","pubTimestamp":1711018664,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月21日 - Becton Dickinson   公司周四表示，将增加国内医用注射器的产量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0289961442.SGD","LU0289739343.SGD","LU1571399168.USD","LU1854103824.USD","BK4082","BK4585","LU0511384066.AUD","LU1854104046.USD","BK4504","LU0266013472.USD","BDX"],"gpt_icon":0},{"id":"2419941549","title":"多肽龙头翰宇药业出海再迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2419941549","media":"中国科技新闻网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419941549?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:25","pubTimestamp":1710491152,"startTime":"0","endTime":"0","summary":"3月12日,全球化医疗器械创新龙头碧迪医疗到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。事实上,正如翰宇药业董事长曾少贵所说,公司国际化战略布局已进入收获期,利拉鲁肽、司美格鲁肽、醋酸格拉替雷、西曲瑞克等产品的以美国为首的海外注册申报工作均顺利推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1854104046.USD","LU0289739343.SGD","LU0511384066.AUD","BK4082","LU0266013472.USD","LU1854103824.USD","BK4504","BK4585","LU0289961442.SGD","BK4588","LU1571399168.USD","BDX"],"gpt_icon":0},{"id":"2408674300","title":"美国研究综述-Atlassian、Solo Brands、WEC Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2408674300","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408674300?lang=zh_cn&edition=full","pubTime":"2024-02-02 17:31","pubTimestamp":1706866281,"startTime":"0","endTime":"0","summary":"    路透2月2日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Atlassian、Solo Brands 和 WEC Energy。要闻 * Atlassian Corp   ：Canaccord Genuity将目标价从240美元上调至260美元 * Euronet Worldwide Inc   ：Stephens将目标价从等权重上调至增持 * Roper Technologies Inc   ：Raymond James将目标价从572美元上调至620美元 * Solo Brands Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","FNF","LU0289961442.SGD","DECK","BC","CTVA","CLB","DOV","DGII","HON","LU0820561909.HKD","BK4146","BXP","AAPL","EZPW","AOS","ENSG","HOLX","AMZN","TECH","TEAM","ALGM","CLX","AROW","CHRW","LU1721427968.SGD","FCFS","GGG","BK4099","LU2095319765.USD","BSIG","BK4566","CAH","AVB","BR","DTC","FLWS","ITW","WEC","LU2210150020.SGD","BZH","EEFT","BALL","CVGW","COST","ELF","RACE","LU0310800965.SGD","BDX","BV"],"gpt_icon":0},{"id":"2408704639","title":"Becton Dickinson and Co 公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2408704639","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408704639?lang=zh_cn&edition=full","pubTime":"2024-02-01 22:34","pubTimestamp":1706798047,"startTime":"0","endTime":"0","summary":"   * Becton Dickinson and Co   公布的截至12月底的季度调整后每股收益为2.68美元，低于去年同期的每股收益2.98美元。13 位分析师对该季度的平均预期为每股收益 2.40 美元。华尔街预期为每股收益 2.37 美元至 2.48 美元。* Becton Dickinson 公司公布的本季度每股收益为 96 美分。* 公司季度净收入为 2.81 亿美元。* 本季度 Becton Dickinson and Co 的股价下跌了 2.1%。华尔街对 Becton Dickinson and Co 的 12 个月目标价中位数为 280.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","LU0289961442.SGD","LU0511384066.AUD","BK4504","BDXA","BK4082","BK4585","LU0266013472.USD","LU0289739343.SGD","LU1571399168.USD","BDX","BK4588","LU1854103824.USD"],"gpt_icon":0},{"id":"2408104687","title":"BUZZ-第一季度收入不及预期，Becton Dickinson 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2408104687","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408104687?lang=zh_cn&edition=full","pubTime":"2024-02-01 21:02","pubTimestamp":1706792526,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    2月1日 - ** 医疗设备制造商Becton Dickinson   股价盘前下跌2.6%，至232.69美元。** 公司季度营收47.1亿美元，低于分析师平均预期的47.3亿美元 ** BDX的生命科学部门（通过该部门销售诊断设备）第一季度销售额为12.9亿美元，低于分析师预期的13.1亿美元。 ** 该公司报告的第一季度 利润为 2.68 美元，低于分析师平均预期的 2.40 美元 - LSEG 数据** 截至上次收盘，股价在过去 12 个月下跌了 6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU0511384066.AUD","LU1571399168.USD","LU0289739343.SGD","LU1854103824.USD","LU0289961442.SGD","LU1854104046.USD","BK4585","BK4082","BK4504","BDX","BUZZ","BK4588"],"gpt_icon":0},{"id":"2408811266","title":"手术器械强劲增长，百通迪金森上调 2024 年利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2408811266","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408811266?lang=zh_cn&edition=full","pubTime":"2024-02-01 20:20","pubTimestamp":1706790043,"startTime":"0","endTime":"0","summary":"根据 LSEG 的数据，第一季度 Becton Dickinson 公司提供手术和重症监护设备的介入部门的销售额为 11.9 亿美元，高于预期的 11.8 亿美元。同时销售针头、注射器和其他此类医疗产品的 Becton Dickinson 公司，调整后每股利润为 2.68 美元，超过了分析师预计的每股 2.40 美元。经调整后，这家总部位于新泽西州的公司目前预计 2024 财年的每股收益将在 12.82 美元至 13.06 美元之间，高于此前预测的每股 12.70 美元至 13.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","LU2125909247.SGD","LU0289961442.SGD","LU0528227936.USD","LU0708995401.HKD","LU2265009873.SGD","SG9999002232.USD","LU1989764664.SGD","BK4007","BDX","BK4559","LU1989772923.USD","IE00B19Z3B42.SGD","BK4585","TMO","BK4588","LU1989764748.USD","SG9999001176.USD","BK4550","LU1066053197.SGD","LU2063271972.USD","BK4533","JNJ","IE00BJJMRZ35.SGD","LU1804176565.USD","LU2264538146.SGD","BK4534","LU1571399168.USD","BK4082","LU0011850046.USD","SG9999002224.SGD","LU1989771016.USD","LU0943347566.SGD","IE0002270589.USD","BK4548","LU1917777945.USD","DHR","LU2468319806.SGD","BK4535","BK4532","LU1280957306.USD","LU1066051498.USD","LU0097036916.USD","LU0109391861.USD","BSX","LU1923622614.USD","LU0689472784.USD","LU0353189763.USD","LU0820561909.HKD","BK4121"],"gpt_icon":0},{"id":"2407351133","title":"Becton Dickinson and Co   预计每股收益2.40美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2407351133","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2407351133?lang=zh_cn&edition=full","pubTime":"2024-01-30 21:48","pubTimestamp":1706622518,"startTime":"0","endTime":"0","summary":"   * Becton Dickinson and Co    将于2月1日公布截至2023年12月31日的财报，预计季度收入将有所增长。* 根据LSEG的数据，11位分析师的平均预期显示，这家总部位于新泽西州富兰克林湖区的公司的营收预计将从去年同期的45.9亿美元增长3.2%，达到47.32亿美元。   * LSEG 的分析师平均预期 Becton Dickinson and Co 每股收益为 2.40 美元。* 华尔街对 Becton Dickinson and Co 的 12 个月目标价中位数为 280.00 美元，高于其上次收盘价 237.85 美元。1月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX","BDXA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bd.com","stockEarnings":[{"period":"1week","weight":0.0222},{"period":"1month","weight":-0.0302},{"period":"3month","weight":-0.014},{"period":"6month","weight":-0.0148},{"period":"1year","weight":-0.1274},{"period":"ytd","weight":-0.0522}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.1427},{"period":"1year","weight":0.2266},{"period":"ytd","weight":0.1669}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"碧迪医疗器械有限公司于1906年11月根据新泽西州法律注册成立。该公司是一家全球性的医疗技术公司，从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。公司提供客户解决方案，重点是改善药物管理和患者安全；支持感染预防实践；配备手术和介入手术；改进药物输送；协助麻醉护理；加强传染病和癌症的诊断；促进细胞研究和应用；支持糖尿病的管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.038615},{"month":2,"riseRate":0.5,"avgChangeRate":0.004773},{"month":3,"riseRate":0.568182,"avgChangeRate":-0.003408},{"month":4,"riseRate":0.511111,"avgChangeRate":0.007201},{"month":5,"riseRate":0.488889,"avgChangeRate":0.013555},{"month":6,"riseRate":0.622222,"avgChangeRate":0.006927},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.001895},{"month":8,"riseRate":0.636364,"avgChangeRate":0.008515},{"month":9,"riseRate":0.386364,"avgChangeRate":-0.001838},{"month":10,"riseRate":0.5,"avgChangeRate":0.007697},{"month":11,"riseRate":0.659091,"avgChangeRate":0.022341},{"month":12,"riseRate":0.681818,"avgChangeRate":0.02022}],"exchange":"NYSE","name":"碧迪医疗","nameEN":"Becton Dickinson"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供碧迪医疗(BDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"碧迪医疗,BDX,碧迪医疗股票,碧迪医疗股票老虎,碧迪医疗股票老虎国际,碧迪医疗行情,碧迪医疗股票行情,碧迪医疗股价,碧迪医疗股市,碧迪医疗股票价格,碧迪医疗股票交易,碧迪医疗股票购买,碧迪医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供碧迪医疗(BDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}